Alzheimer’s Agent Fails; Antiseizure Drug Use Rises; Stress and Post-COVID Outcomes

Phase III studies of investigational gantenerumab did not meet their primary endpoints of slowing clinical decline in early Alzheimer’s disease, the Roche Group said. Beta-amyloid removal also was lower than expected with the drug.

Read More


Detecting Alzheimer’s Gets Easier with a Simple Blood Test

Source: Advances in technologies to detect early signs of disease from a blood sample are helping doctors to identify the memory-robbing disorder more accurately and to screen participants more quickly for trials of potential treatments.

Read More

About Us

GCG Global Healthcare are specialists in healthcare excellence. Driven by a desire to improve healthcare and clinical solutions for everyone – patients, medical professionals and facilities. We aim to foster a culture of excellence through collaboration with industry experts and thought leaders to deliver better outcomes.